NO20073662L - Antigenbindende molekyler som binder EGFR, vektorer kodende for disse samt anvendelser derav - Google Patents

Antigenbindende molekyler som binder EGFR, vektorer kodende for disse samt anvendelser derav

Info

Publication number: NO20073662L
Authority: NO; Norway
Prior art keywords: abm; antigen; binding molecules; vectors encoding; bind egfr
Prior art date: 2005-02-07

Application number

NO20073662A

Other languages

English (en)

Norwegian (no)

Inventor

Pablo Umana

Ekkehard Mossner

Original Assignee

Glycart Biotechnology Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-07

Filing date

2007-07-17

Publication date

2007-11-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36777599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073662(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-17 Application filed by Glycart Biotechnology Ag filed Critical Glycart Biotechnology Ag

2007-11-05 Publication of NO20073662L publication Critical patent/NO20073662L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20073662A 2005-02-07 2007-07-17 Antigenbindende molekyler som binder EGFR, vektorer kodende for disse samt anvendelser derav NO20073662L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65011505P	2005-02-07	2005-02-07
PCT/IB2006/000238 WO2006082515A2 (en)	2005-02-07	2006-02-07	Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof

Publications (1)

Publication Number	Publication Date
NO20073662L true NO20073662L (no)	2007-11-05

Family

ID=36777599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20073662A NO20073662L (no)	2005-02-07	2007-07-17	Antigenbindende molekyler som binder EGFR, vektorer kodende for disse samt anvendelser derav

Country Status (28)

Country	Link
US (8)	US7722867B2 (es)
EP (4)	EP3660049A1 (es)
JP (2)	JP5336089B2 (es)
KR (2)	KR101569300B1 (es)
CN (2)	CN103981190A (es)
AR (1)	AR052285A1 (es)
AU (1)	AU2006211037B2 (es)
BR (1)	BRPI0607315B1 (es)
CA (1)	CA2596835C (es)
CR (2)	CR9236A (es)
DK (1)	DK1871805T3 (es)
ES (1)	ES2755976T3 (es)
HK (2)	HK1199470A1 (es)
HR (1)	HRP20192134T1 (es)
IL (1)	IL184498A (es)
LT (1)	LT1871805T (es)
MA (1)	MA29279B1 (es)
MX (1)	MX2007008619A (es)
NO (1)	NO20073662L (es)
NZ (1)	NZ556286A (es)
PL (1)	PL1871805T3 (es)
PT (1)	PT1871805T (es)
RS (1)	RS59761B1 (es)
RU (2)	RU2488597C2 (es)
SI (1)	SI1871805T1 (es)
TW (1)	TWI387602B (es)
UA (1)	UA95068C2 (es)
WO (1)	WO2006082515A2 (es)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2180044A1 (en)	2001-08-03	2010-04-28	GlycArt Biotechnology AG	Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CN103981190A (zh) *	2005-02-07	2014-08-13	罗氏格黎卡特股份公司	结合egfr的抗原结合分子，编码它的载体，及其应用
AR062223A1 (es)	2006-08-09	2008-10-22	Glycart Biotechnology Ag	Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CA2687819A1 (en)	2007-06-06	2008-12-11	F.Hoffmann-La Roche Ag	Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
WO2010034441A1 (en) *	2008-09-26	2010-04-01	F. Hoffmann-La Roche Ag	Bispecific anti-egfr/anti-igf-1r antibodies
CA2754646A1 (en) *	2009-03-31	2010-10-07	Roche Glycart Ag	Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
AR075982A1 (es) *	2009-03-31	2011-05-11	Roche Glycart Ag	Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
WO2010112194A1 (en)	2009-04-02	2010-10-07	F. Hoffmann-La Roche Ag	Antigen-binding polypeptides and multispecific antibodies comprising them
EP2414391B1 (en)	2009-04-02	2018-11-28	Roche Glycart AG	Multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2011010158A (es)	2009-04-07	2011-10-17	Roche Glycart Ag	Anticuerpos biespecificos anti-erbb-2/anti-c-met.
SI2417156T1 (sl)	2009-04-07	2015-06-30	Roche Glycart Ag	Trivalentna, bispecifiäśna protitelesa
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
WO2011034605A2 (en)	2009-09-16	2011-03-24	Genentech, Inc.	Coiled coil and/or tether containing protein complexes and uses thereof
MX2012007676A (es) *	2009-12-29	2012-08-03	Hoffmann La Roche	Nueva formulacion de anticuerpo.
JP6012473B2 (ja) *	2010-01-11	2016-10-25	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
US20110200595A1 (en) *	2010-02-18	2011-08-18	Roche Glycart	TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
TW201138821A (en) *	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
CN101875697B (zh) *	2010-04-15	2014-04-30	北京天广实生物技术股份有限公司	新型抗egfr人源抗体tgm10的设计及其应用
JP5758004B2 (ja)	2010-08-24	2015-08-05	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102153647B (zh) *	2011-01-27	2012-07-04	中国人民解放军军事医学科学院生物工程研究所	一种抗egfr人源化抗体l3-h3及其编码基因与应用
JP2014511147A (ja)	2011-02-10	2014-05-12	ロシュグリクアートアーゲー	改善された免疫療法
AR085403A1 (es)	2011-02-28	2013-09-25	Hoffmann La Roche	Proteinas monovalentes que se unen a antigenos
CA2825081A1 (en)	2011-02-28	2012-09-07	Birgit Bossenmaier	Antigen binding proteins
US9152861B2 (en) *	2011-03-04	2015-10-06	Nec Corporation	Individual product identification system, individual product identification method, and device and program used by same
CN103748114B (zh)	2011-08-23	2017-07-21	罗切格利卡特公司	T细胞活化性双特异性抗原结合分子
WO2013026837A1 (en)	2011-08-23	2013-02-28	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
DK2748202T3 (en)	2011-08-23	2018-09-17	Roche Glycart Ag	BISPECIFIC ANTI-BINDING MOLECULES
JP6159724B2 (ja)	2011-08-23	2017-07-05	ロシュグリクアートアーゲー	Ｔ細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
KR20140054268A (ko)	2011-08-26	2014-05-08	메리맥 파마슈티컬즈, 인크.	탠덤 fc 이중특이적 항체
MX2014002996A (es)	2011-09-23	2014-05-28	Roche Glycart Ag	Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
WO2013113641A1 (en)	2012-01-31	2013-08-08	Roche Glycart Ag	Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
RU2644341C2 (ru)	2012-02-10	2018-02-08	Дженентек, Инк.	Одноцепочечные антитела и другие гетеромультимеры
JP2015511702A (ja)	2012-03-02	2015-04-20	ロシュグリクアートアーゲー	Ａｄｃｃ増強抗体を用いた癌治療のための予測バイオマーカー
US20150231220A1 (en) *	2012-03-27	2015-08-20	Mogam Biotechnology Research Institute	Epitopes of epidermal growth factor receptor surface antigen and use thereof
JP6441792B2 (ja) *	2012-05-17	2018-12-19	ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｅｇｆｒに結合する抗原結合蛋白質
ES2597228T3 (es)	2012-06-27	2017-01-17	F. Hoffmann-La Roche Ag	Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
EP2867254B1 (en)	2012-06-27	2017-10-25	F. Hoffmann-La Roche AG	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX365382B (es)	2012-08-07	2019-05-31	Roche Glycart Ag	Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
EP2904016B1 (en)	2012-10-08	2018-11-14	Roche Glycart AG	Fc-free antibodies comprising two fab-fragments and methods of use
US9180185B2 (en) *	2013-01-11	2015-11-10	Hoffman-La Roche Inc.	Combination therapy of anti-HER3 antibodies
WO2014114595A1 (en)	2013-01-23	2014-07-31	Roche Glycart Ag	Predictive biomarker for cancer treatment with adcc-enhanced antibodies
KR20150122761A (ko)	2013-02-26	2015-11-02	로슈 글리카트 아게	Ｔ 세포 활성화 항원 결합 분자
WO2014131711A1 (en)	2013-02-26	2014-09-04	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
CN110437337B (zh)	2013-02-26	2024-07-30	罗切格利卡特公司	双特异性t细胞活化性抗原结合分子
WO2014138449A1 (en)	2013-03-06	2014-09-12	Merrimack Pharmaceuticals, Inc.	Anti-c-met tandem fc bispecific antibodies
KR20150144804A (ko) *	2013-04-22	2015-12-28	글리코토페 게엠베하	낮은 푸코실화를 갖는 항ｅｇｆｒ 항체를 이용한 항암 치료
EP3055329B1 (en)	2013-10-11	2018-06-13	F. Hoffmann-La Roche AG	Multispecific domain exchanged common variable light chain antibodies
MX2016006301A (es)	2013-11-13	2016-12-16	Zymeworks Inc	Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
TWI695013B (zh) *	2014-04-10	2020-06-01	台灣浩鼎生技股份有限公司	抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
SI3608337T1 (sl)	2014-08-04	2024-07-31	F. Hoffmann - La Roche Ag	Biospecifične molekule za aktivacijo celic T in antigensko vezavo
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
SG11201701388UA (en)	2014-10-23	2017-03-30	Innate Pharma	Treatment of cancers using anti-nkg2a agents
EP3747905A1 (en)	2014-11-20	2020-12-09	F. Hoffmann-La Roche AG	Common light chains and methods of use
AU2015348595B2 (en)	2014-11-20	2021-06-10	F. Hoffmann-La Roche Ag	T cell activating bispecific antigen binding molecules against FOLR1 and CD3
KR20240024318A (ko)	2014-11-20	2024-02-23	에프. 호프만-라 로슈 아게	T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법
PL3227332T3 (pl)	2014-12-03	2020-06-15	F. Hoffmann-La Roche Ag	Wielospecyficzne przeciwciała
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055385A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
EP3356409A2 (en)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispecific t cell activating antigen binding molecules
US20170096485A1 (en)	2015-10-02	2017-04-06	Hoffmann-La Roche Inc.	Bispecific t cell activating antigen binding molecules
WO2017055395A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055393A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
JP6937746B2 (ja)	2015-10-02	2021-09-22	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗ｃｄ１９×ｃｄ３ｔ細胞活性化抗原結合分子
EP3356410B1 (en)	2015-10-02	2021-10-20	F. Hoffmann-La Roche AG	Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
CN108290954B (zh)	2015-12-09	2022-07-26	豪夫迈·罗氏有限公司	Ii型抗cd20抗体用于降低抗药物抗体形成
CN108368179B (zh)	2016-01-08	2022-08-23	豪夫迈·罗氏有限公司	使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
UA127308C2 (uk)	2016-03-22	2023-07-19	Ф. Хоффманн-Ля Рош Аг	Активована протеазою біспецифічна молекула, яка зв'язує т-клітини
CN108884170A (zh)	2016-03-22	2018-11-23	豪夫迈·罗氏有限公司	蛋白酶活化的t细胞双特异性分子
US10753936B2 (en)	2016-07-22	2020-08-25	Van Andel Research Institute	Method of detecting the level of a glycan
WO2018060301A1 (en)	2016-09-30	2018-04-05	F. Hoffmann-La Roche Ag	Bispecific antibodies against cd3
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
IL269531B2 (en)	2017-03-27	2024-10-01	Hoffmann La Roche	Improved antigen binding receptors
MA49355A (fr)	2017-03-27	2020-02-05	Hoffmann La Roche	Formats de récepteurs de liaison d'antigène améliorés
SG11201909205YA (en)	2017-04-03	2019-11-28	Hoffmann La Roche	Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CN110382525B (zh)	2017-04-03	2023-10-20	豪夫迈·罗氏有限公司	免疫缀合物
SG11201909218RA (en)	2017-04-03	2019-11-28	Hoffmann La Roche	Antibodies binding to steap-1
SI3606954T1 (sl)	2017-04-05	2022-10-28	F. Hoffmann - La Roche Ag	Protitelesa proti LAG3
MX2019012187A (es)	2017-04-13	2019-11-25	Hoffmann La Roche	Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
GB201710836D0 (en) *	2017-07-05	2017-08-16	Ucl Business Plc	ROR1 Car T-Cells
CN107881160A (zh) *	2017-08-11	2018-04-06	百奥泰生物科技(广州)有限公司	一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
US11802154B2 (en)	2017-12-20	2023-10-31	Alexion Pharmaceuticals, Inc.	Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals, Inc.	Liquid formulations of anti-cd200 antibodies
TWI805665B (zh)	2017-12-21	2023-06-21	瑞士商赫孚孟拉羅股份公司	結合hla-a2/wt1之抗體
EP3729080B1 (en)	2017-12-21	2023-04-19	F. Hoffmann-La Roche AG	Universal reporter cell assay for specificity test of novel antigen binding moieties
CN111511400A (zh)	2017-12-29	2020-08-07	豪夫迈·罗氏有限公司	抗vegf抗体及其使用方法
SG11202007390YA (en)	2018-02-08	2020-08-28	Genentech Inc	Bispecific antigen-binding molecules and methods of use
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
SG11202009542PA (en)	2018-03-29	2020-10-29	Genentech Inc	Modulating lactogenic activity in mammalian cells
AU2019276640B2 (en) *	2018-06-01	2024-12-05	Musc Foundation For Research Development	Glycan analysis of proteins and cells
TW202428614A (zh)	2018-12-21	2024-07-16	瑞士商赫孚孟拉羅股份公司	結合cd3之抗體
AU2019410073B2 (en)	2018-12-21	2024-08-01	F. Hoffmann-La Roche Ag	Tumor-targeted agonistic CD28 antigen binding molecules
WO2020127628A1 (en)	2018-12-21	2020-06-25	F. Hoffmann-La Roche Ag	Tumor-targeted superagonistic cd28 antigen binding molecules
US11130804B2 (en)	2018-12-21	2021-09-28	Hoffmann-La Roche Inc.	Antibody that binds to VEGF and IL-1beta and methods of use
US20220025056A1 (en)	2018-12-26	2022-01-27	Innate Pharma	Leucocyte immunoglobulin-like receptor neutralizing antibodies
KR20220025848A (ko)	2019-06-26	2022-03-03	에프. 호프만-라 로슈 아게	Cea 및 4-1bbl에 결합하는 항체의 융합
WO2021001289A1 (en)	2019-07-02	2021-01-07	F. Hoffmann-La Roche Ag	Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119382A1 (es)	2019-07-12	2021-12-15	Hoffmann La Roche	Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
KR20220038767A (ko)	2019-07-26	2022-03-29	에이비엘바이오 주식회사	항-egfr/항-4-1bb 이중 특이 항체 및 이의 용도
MX2022001156A (es)	2019-07-31	2022-02-22	Hoffmann La Roche	Anticuerpos que se fijan a gprc5d.
JP2022543551A (ja)	2019-07-31	2022-10-13	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｇｐｒｃ５ｄに結合する抗体
KR20220064980A (ko)	2019-09-18	2022-05-19	제넨테크, 인크.	항 klk7 항체, 항 klk5 항체, 다중특이적 항 klk5/klk7 항체, 및 사용 방법
JP7296467B2 (ja)	2019-12-18	2023-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体
CN111018990A (zh) *	2020-02-10	2020-04-17	张喜田	一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
TW202202620A (zh)	2020-03-26	2022-01-16	美商建南德克公司	經修飾之哺乳動物細胞
CN115485028A (zh)	2020-04-15	2022-12-16	豪夫迈·罗氏有限公司	免疫缀合物
KR20230010240A (ko)	2020-05-11	2023-01-18	에프. 호프만-라 로슈 아게	변형된 pbmc 및 면역접합체를 이용한 병용 요법
AR122569A1 (es)	2020-06-08	2022-09-21	Hoffmann La Roche	Anticuerpos anti-vhb y métodos de uso
EP4168456A1 (en)	2020-06-19	2023-04-26	F. Hoffmann-La Roche AG	Antibodies binding to cd3
CA3177239A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Protease-activated t cell bispecific antibodies
MX2022015203A (es)	2020-06-19	2023-01-05	Hoffmann La Roche	Moleculas de union al dominio fc de activacion inmunitaria.
MX2022015887A (es)	2020-06-19	2023-01-24	Hoffmann La Roche	Anticuerpos que se unen a cd3 y folr1.
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
CN115916825A (zh)	2020-06-19	2023-04-04	豪夫迈·罗氏有限公司	与cd3和cd19结合的抗体
PH12022553167A1 (en)	2020-06-23	2024-03-04	Hoffmann La Roche	Agonistic cd28 antigen binding molecules targeting her2
WO2021262783A1 (en)	2020-06-24	2021-12-30	Genentech, Inc.	Apoptosis resistant cell lines
JP2023531067A (ja)	2020-06-25	2023-07-20	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
KR20230037578A (ko)	2020-07-10	2023-03-16	에프. 호프만-라 로슈 아게	암 세포에 결합하고 방사성 핵종을 상기 세포로 표적화하는 항체
KR20230038735A (ko)	2020-07-17	2023-03-21	제넨테크, 인크.	항-notch2 항체 및 이용 방법
TW202221021A (zh)	2020-08-03	2022-06-01	瑞士商赫孚孟拉羅股份公司	改良之抗原結合受體
CN116648507A (zh)	2020-08-28	2023-08-25	基因泰克公司	宿主细胞蛋白的CRISPR/Cas9多重敲除
EP4208201A1 (en)	2020-09-04	2023-07-12	F. Hoffmann-La Roche AG	Antibody that binds to vegf-a and ang2 and methods of use
TW202233671A (zh)	2020-10-20	2022-09-01	美商建南德克公司	Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
CN116507640A (zh)	2020-10-28	2023-07-28	豪夫迈·罗氏有限公司	改善的抗原结合受体
WO2022148853A1 (en)	2021-01-11	2022-07-14	F. Hoffmann-La Roche Ag	Immunoconjugates
MX2023008084A (es)	2021-01-12	2023-07-13	Hoffmann La Roche	Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas.
AU2022207624A1 (en)	2021-01-13	2023-07-13	F. Hoffmann-La Roche Ag	Combination therapy
EP4288458A1 (en)	2021-02-03	2023-12-13	Genentech, Inc.	Multispecific binding protein degrader platform and methods of use
AR125074A1 (es)	2021-03-12	2023-06-07	Genentech Inc	Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
CN117157312A (zh)	2021-03-30	2023-12-01	豪夫迈·罗氏有限公司	蛋白酶活化的多肽
IL307501A (en)	2021-04-19	2023-12-01	Hoffmann La Roche	Modified mammalian cells
TW202243689A (zh)	2021-04-30	2022-11-16	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
JP2024521107A (ja)	2021-05-21	2024-05-28	ジェネンテック，インコーポレイテッド	目的の組換え産物を産生するための修飾細胞
AR126009A1 (es)	2021-06-02	2023-08-30	Hoffmann La Roche	Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4370545A1 (en)	2021-07-12	2024-05-22	Genentech, Inc.	Structures for reducing antibody-lipase binding
JP2024527606A (ja)	2021-07-14	2024-07-25	ジェネンテック，インコーポレイテッド	抗ｃ－ｃモチーフケモカイン受容体８（ｃｃｒ８）抗体及び使用方法
JP2024528631A (ja)	2021-07-22	2024-07-30	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	ヘテロ二量体Ｆｃドメイン抗体
JP2024528217A (ja)	2021-08-03	2024-07-26	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗体および使用方法
JP2024537335A (ja)	2021-10-14	2024-10-10	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	新規インターロイキン－７イムノコンジュゲート
CN118139648A (zh)	2021-10-14	2024-06-04	豪夫迈·罗氏有限公司	用于治疗癌症的替代的PD1-IL7v免疫缀合物
IL312652A (en)	2021-11-25	2024-07-01	Hoffmann La Roche	Enhanced receptors for antigen binding
WO2023094569A1 (en)	2021-11-26	2023-06-01	F. Hoffmann-La Roche Ag	Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
CN116333117B (zh) *	2021-12-16	2024-04-26	徕特康(苏州)生物制药有限公司	抗表皮生长因子受体抗体及其制备方法和用途
CN116333116B (zh) *	2021-12-16	2024-03-05	徕特康(苏州)生物制药有限公司	抗表皮生长因子受体抗体及其制备方法和用途
TW202340251A (zh)	2022-01-19	2023-10-16	美商建南德克公司	抗ｎｏｔｃｈ２抗體及結合物及其使用方法
CN118510815A (zh)	2022-02-11	2024-08-16	江苏恒瑞医药股份有限公司	免疫缀合物及其用途
WO2023180511A1 (en)	2022-03-25	2023-09-28	F. Hoffmann-La Roche Ag	Improved chimeric receptors
AR129268A1 (es)	2022-05-11	2024-08-07	Hoffmann La Roche	Anticuerpo que se une a vegf-a e il6 y métodos de uso
WO2024030856A2 (en)	2022-08-01	2024-02-08	Flagship Pioneering Innovations Vii, Llc	Immunomodulatory proteins and related methods
WO2024068705A1 (en)	2022-09-29	2024-04-04	F. Hoffmann-La Roche Ag	Protease-activated polypeptides
AU2023356326A1 (en)	2022-10-06	2025-03-27	Bicara Therapeutics Inc.	Multispecific proteins and related methods
TW202421664A (zh)	2022-10-07	2024-06-01	美商建南德克公司	用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
TW202423969A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及蛋白酶體抑制劑之組合療法
TW202423970A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｃｄ３８抗體之組合療法
TW202430211A (zh)	2022-10-10	2024-08-01	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｉｍｉｄ之組合療法
WO2024094741A1 (en)	2022-11-03	2024-05-10	F. Hoffmann-La Roche Ag	Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
WO2024104933A1 (en)	2022-11-15	2024-05-23	F. Hoffmann-La Roche Ag	Antigen binding molecules
TW202432607A (zh)	2023-01-18	2024-08-16	美商建南德克公司	多特異性抗體及其用途
WO2024153722A1 (en)	2023-01-20	2024-07-25	F. Hoffmann-La Roche Ag	Immunoconjugates
WO2024156672A1 (en)	2023-01-25	2024-08-02	F. Hoffmann-La Roche Ag	Antibodies binding to csf1r and cd3
TW202438515A (zh)	2023-02-06	2024-10-01	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	免疫調節組合物及相關方法
WO2024184287A1 (en)	2023-03-06	2024-09-12	F. Hoffmann-La Roche Ag	Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024191785A1 (en)	2023-03-10	2024-09-19	Genentech, Inc.	Fusions with proteases and uses thereof
US20240327522A1 (en)	2023-03-31	2024-10-03	Genentech, Inc.	Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024208777A1 (en)	2023-04-03	2024-10-10	F. Hoffmann-La Roche Ag	All-in-one agonistic antibodies
WO2024208776A1 (en)	2023-04-03	2024-10-10	F. Hoffmann-La Roche Ag	Agonistic split antibodies
WO2024231320A1 (en)	2023-05-08	2024-11-14	F. Hoffmann-La Roche Ag	Targeted interferon alpha fusion proteins and methods of use
WO2024238537A1 (en)	2023-05-16	2024-11-21	F. Hoffmann-La Roche Ag	Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024246083A1 (en)	2023-06-01	2024-12-05	F. Hoffmann-La Roche Ag	Bispecific antibodies targeting bcma and cd28
WO2024246086A1 (en)	2023-06-01	2024-12-05	F. Hoffmann-La Roche Ag	Immunostimulatory antigen binding molecules that specifically bind to bcma
WO2024263761A1 (en)	2023-06-22	2024-12-26	Genentech, Inc.	Antibodies and uses thereof
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025021838A1 (en)	2023-07-26	2025-01-30	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2025040567A1 (en)	2023-08-18	2025-02-27	F. Hoffmann-La Roche Ag	Protease activatable fc domain binding molecules

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2820404A (en)	1954-11-23	1958-01-21	Kwei Chung Shu	Photoprinting apparatus
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
WO1992015683A1 (en)	1991-03-06	1992-09-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Humanized and chimeric monoclonal antibodies
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
GB9401182D0 (en) *	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
MX9800684A (es)	1995-07-27	1998-04-30	Genentech Inc	Formulacion de proteinas liofilizadas isotonicas estables.
US6001358A (en)	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
DE19746874A1 (de)	1997-10-23	1999-04-29	Qiagen Gmbh	Verfahren zur Isolierung und Reinigung von Nukleinsäuren an hydrophoben Oberflächen - insbesondere unter Verwendung hydrophober Membranen
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6322980B1 (en)	1999-04-30	2001-11-27	Aclara Biosciences, Inc.	Single nucleotide detection using degradation of a fluorescent sequence
ES2571230T3 (es)	1999-04-09	2016-05-24	Kyowa Hakko Kirin Co Ltd	Procedimiento para controlar la actividad de una molécula inmunofuncional
CN101073668A (zh) *	1999-04-28	2007-11-21	德克萨斯大学董事会	用于通过选择性抑制vegf来治疗癌症的组合物和方法
CN1451048A (zh)	2000-07-31	2003-10-22	比奥莱克斯公司	在浮萍中表达生物活性多肽
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002213357A1 (en)	2000-10-20	2002-05-06	Idec Pharmaceuticals Corporation	Variant igg3 rituxan r and therapeutic use thereof
DK1392359T4 (da) *	2001-05-11	2013-06-10	Ludwig Inst For Cancer Res Ltd	Specifikke bindingsproteiner og deres anvendelser.
CZ200438A3 (cs) *	2001-06-13	2004-06-16	Genmab A/S	Název neuveden
US7321026B2 (en)	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
EP2298809A3 (en)	2001-07-12	2012-02-15	FOOTE, Jefferson	Super humanized antibodies
EP2180044A1 (en)	2001-08-03	2010-04-28	GlycArt Biotechnology AG	Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US7084257B2 (en)	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
DE60232265D1 (de)	2001-10-25	2009-06-18	Genentech Inc	Glycoprotein-zusammensetzungen
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
JP4820055B2 (ja)	2001-12-27	2011-11-24	グライコフィ，インコーポレイテッド	哺乳動物型糖質構造を操作するための方法
US7432063B2 (en)	2002-02-14	2008-10-07	Kalobios Pharmaceuticals, Inc.	Methods for affinity maturation
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
AU2003219402B2 (en)	2002-03-19	2008-05-08	Stichting Dienst Landbouwkundig Onderzoek	GnTIII (UDP-n-acethylglucosamine:beta-D mannoside beta (1,4)-N-acethylglucosaminy ltransferase III) expression in plants
CA2492671C (en)	2002-03-22	2012-04-17	Aprogen, Inc.	Humanized antibody and process for preparing same
JP4191612B2 (ja)	2002-03-28	2008-12-03	アドバンスト・マイクロ・ディバイシズ・インコーポレイテッド	同期データ検出ユニットおよび方法
US20030190689A1 (en)	2002-04-05	2003-10-09	Cell Signaling Technology,Inc.	Molecular profiling of disease and therapeutic response using phospho-specific antibodies
DE60336548D1 (de)	2002-04-09	2011-05-12	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498485A4 (en)	2002-04-09	2006-09-06	Kyowa Hakko Kogyo Kk	CELLS WITH MODIFIED GENOM
EP1498490A4 (en)	2002-04-09	2006-11-29	Kyowa Hakko Kogyo Kk	PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481925A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Therapeutic agent for patients having human fc.gamma.riiia
US20040259150A1 (en)	2002-04-09	2004-12-23	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
AU2003251597A1 (en)	2002-06-19	2004-01-06	Abgenix, Inc.	Method for predicting response to epidermal growth factor receptor-directed therapy
DK1539966T3 (da)	2002-09-12	2010-10-04	Greenovation Biotech Gmbh	Fremgangsmåde til fremstilling af proteiner
RU2325186C2 (ru) *	2002-09-27	2008-05-27	Ксенкор, Инк.	АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО
US6938692B2 (en)	2002-12-17	2005-09-06	Halliburton Energy Services, Inc.	Permeable cement composition and method for preparing the same
AU2003294912B2 (en)	2002-12-20	2009-06-04	Greenovation Biotech Gmbh	Production of heterologous glycosylated proteins in bryophyte cells
WO2004063351A2 (en)	2003-01-09	2004-07-29	Macrogenics, Inc.	IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
KR101292000B1 (ko)	2003-01-22	2013-08-01	로슈 글리카트 아게	융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이증가된 항체를 생성하기 위한 이의 용도
RS55723B1 (sr)	2003-11-05	2017-07-31	Roche Glycart Ag	Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
US20050142133A1 (en) *	2003-12-03	2005-06-30	Xencor, Inc.	Optimized proteins that target the epidermal growth factor receptor
WO2005056759A2 (en)	2003-12-04	2005-06-23	Xencor, Inc.	Methods of generating variant proteins with increased host string content and compositions thereof
CN103981190A (zh) *	2005-02-07	2014-08-13	罗氏格黎卡特股份公司	结合egfr的抗原结合分子，编码它的载体，及其应用
WO2007031872A2 (en) *	2005-07-13	2007-03-22	L'oréal	Keratin fibre coating composition comprising a liquid fatty phase and a tackifying resin
BR122020020335B1 (pt)	2005-08-26	2023-10-03	Roche Glycart Ag	Anticorpo anti-cd20, composição farmacêutica e uso
AR062223A1 (es) *	2006-08-09	2008-10-22	Glycart Biotechnology Ag	Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
WO2009012181A2 (en) *	2007-07-13	2009-01-22	Ventana Medical Systems, Inc.	Method of identifying diagnostic reagents
WO2010034441A1 (en) *	2008-09-26	2010-04-01	F. Hoffmann-La Roche Ag	Bispecific anti-egfr/anti-igf-1r antibodies

2006
- 2006-02-07 CN CN201410056372.6A patent/CN103981190A/zh active Pending
- 2006-02-07 RS RS20191498A patent/RS59761B1/sr unknown
- 2006-02-07 TW TW095104103A patent/TWI387602B/zh not_active IP Right Cessation
- 2006-02-07 UA UAA200710028A patent/UA95068C2/uk unknown
- 2006-02-07 ES ES06710336T patent/ES2755976T3/es active Active
- 2006-02-07 KR KR1020147002356A patent/KR101569300B1/ko active Active
- 2006-02-07 PL PL06710336T patent/PL1871805T3/pl unknown
- 2006-02-07 US US11/348,526 patent/US7722867B2/en active Active
- 2006-02-07 NZ NZ556286A patent/NZ556286A/en not_active IP Right Cessation
- 2006-02-07 LT LT06710336T patent/LT1871805T/lt unknown
- 2006-02-07 EP EP19198853.4A patent/EP3660049A1/en not_active Withdrawn
- 2006-02-07 SI SI200632361T patent/SI1871805T1/sl unknown
- 2006-02-07 EP EP11176829A patent/EP2404937A1/en not_active Withdrawn
- 2006-02-07 JP JP2007553735A patent/JP5336089B2/ja active Active
- 2006-02-07 AR ARP060100439A patent/AR052285A1/es unknown
- 2006-02-07 MX MX2007008619A patent/MX2007008619A/es active IP Right Grant
- 2006-02-07 EP EP11176828A patent/EP2402374A1/en not_active Withdrawn
- 2006-02-07 RU RU2007133439/10A patent/RU2488597C2/ru not_active Application Discontinuation
- 2006-02-07 CN CN200680004310.4A patent/CN101115773B/zh active Active
- 2006-02-07 EP EP06710336.6A patent/EP1871805B1/en active Active
- 2006-02-07 BR BRPI0607315-8A patent/BRPI0607315B1/pt active IP Right Grant
- 2006-02-07 AU AU2006211037A patent/AU2006211037B2/en not_active Ceased
- 2006-02-07 PT PT67103366T patent/PT1871805T/pt unknown
- 2006-02-07 CA CA2596835A patent/CA2596835C/en active Active
- 2006-02-07 DK DK06710336T patent/DK1871805T3/da active
- 2006-02-07 WO PCT/IB2006/000238 patent/WO2006082515A2/en active Application Filing
2007
- 2007-07-09 IL IL184498A patent/IL184498A/en active IP Right Grant
- 2007-07-09 CR CR9236A patent/CR9236A/es unknown
- 2007-07-17 NO NO20073662A patent/NO20073662L/no not_active Application Discontinuation
- 2007-08-17 US US11/889,981 patent/US7846432B2/en active Active
- 2007-08-31 MA MA30180A patent/MA29279B1/fr unknown
- 2007-09-07 KR KR1020077020499A patent/KR101467566B1/ko active Active
2008
- 2008-05-13 HK HK14112920.4A patent/HK1199470A1/xx unknown
- 2008-05-13 HK HK08105244.5A patent/HK1110873A1/xx unknown
2010
- 2010-11-02 US US12/938,180 patent/US8097436B2/en active Active
2011
- 2011-12-09 US US13/315,989 patent/US8614065B2/en active Active
2012
- 2012-11-19 CR CR20120587A patent/CR20120587A/es unknown
2013
- 2013-02-28 JP JP2013038450A patent/JP5763695B2/ja active Active
- 2013-04-26 RU RU2013119417A patent/RU2610688C2/ru active
- 2013-11-19 US US14/084,303 patent/US9309317B2/en active Active
2016
- 2016-02-23 US US15/050,821 patent/US9957326B2/en active Active
2018
- 2018-04-27 US US15/965,143 patent/US20190106497A1/en not_active Abandoned
2019
- 2019-11-27 HR HRP20192134TT patent/HRP20192134T1/hr unknown
- 2019-12-02 US US16/700,217 patent/US20200332012A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK1871805T3 (da)	2019-12-02
JP2013165711A (ja)	2013-08-29
US20060269545A1 (en)	2006-11-30
MX2007008619A (es)	2007-09-11
CN103981190A (zh)	2014-08-13
IL184498A (en)	2011-08-31
CA2596835C (en)	2019-08-20
PL1871805T3 (pl)	2020-03-31
US20120178106A1 (en)	2012-07-12
JP2008529489A (ja)	2008-08-07
US20080279858A9 (en)	2008-11-13
AU2006211037B2 (en)	2012-05-24
CN101115773B (zh)	2015-06-10
NZ556286A (en)	2010-11-26
CR9236A (es)	2007-11-23
EP2404937A1 (en)	2012-01-11
AR052285A1 (es)	2007-03-07
LT1871805T (lt)	2019-12-10
AU2006211037A1 (en)	2006-08-10
CA2596835A1 (en)	2006-08-10
US20190106497A1 (en)	2019-04-11
WO2006082515A2 (en)	2006-08-10
RU2610688C2 (ru)	2017-02-14
HK1199470A1 (en)	2015-07-03
US9309317B2 (en)	2016-04-12
KR101467566B1 (ko)	2014-12-02
RU2013119417A (ru)	2014-11-10
EP3660049A1 (en)	2020-06-03
EP1871805B1 (en)	2019-09-25
IL184498A0 (en)	2007-10-31
PT1871805T (pt)	2019-12-02
JP5336089B2 (ja)	2013-11-06
US20140227253A1 (en)	2014-08-14
TWI387602B (zh)	2013-03-01
UA95068C2 (uk)	2011-07-11
US8614065B2 (en)	2013-12-24
US7722867B2 (en)	2010-05-25
US20090186019A1 (en)	2009-07-23
EP2402374A1 (en)	2012-01-04
HK1110873A1 (en)	2008-07-25
TW200639181A (en)	2006-11-16
US7846432B2 (en)	2010-12-07
JP5763695B2 (ja)	2015-08-12
WO2006082515A3 (en)	2007-06-14
CN101115773A (zh)	2008-01-30
RU2488597C2 (ru)	2013-07-27
CR20120587A (es)	2013-02-05
MA29279B1 (fr)	2008-02-01
US9957326B2 (en)	2018-05-01
KR20140031985A (ko)	2014-03-13
HRP20192134T1 (hr)	2020-02-21
ES2755976T3 (es)	2020-04-24
KR20070119629A (ko)	2007-12-20
RS59761B1 (sr)	2020-02-28
BRPI0607315B1 (pt)	2022-05-17
KR101569300B1 (ko)	2015-11-13
EP1871805A2 (en)	2008-01-02
US8097436B2 (en)	2012-01-17
SI1871805T1 (sl)	2020-02-28
US20160304614A1 (en)	2016-10-20
RU2007133439A (ru)	2009-03-20
BRPI0607315A2 (pt)	2009-09-01
US20200332012A1 (en)	2020-10-22
US20110111461A1 (en)	2011-05-12

Publication	Publication Date	Title
NO20073662L (no)	2007-11-05	Antigenbindende molekyler som binder EGFR, vektorer kodende for disse samt anvendelser derav
NO20090406L (no)	2009-03-09	Antigen-bindende molekyler som binder EGFR, vektorer som koder for disse og anvendelser derav
NO20062289L (no)	2006-08-03	Antigen bindende molekyler med oket FC reseptor bindende affinitet og effektor funksjon
TW200720439A (en)	2007-06-01	Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
NO20081328L (no)	2008-05-23	Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
CR8389A (es)	2006-10-05	Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas

Legal Events

Date	Code	Title	Description
2017-09-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application